STANDFORD ROOK, the little biotech company, jumped 24p to 166.5p, its highest for more than a year. Talk of a forthcoming link with a major pharmaceuticals group with an asthma treatment was behind the surge.
Two years ago the shares were riding at 635p on the group's TB development. As hopes faded they plunged to a 61.5p low.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments